A recent study reveals that AI-trained models can cut genome analysis errors by up to 73%. This breakthrough enhances genomic data reliability, crucial for early disease detection.

Complete Genomics introduces its DNBSEQ-T7+ high-throughput sequencing platform at AGBT 2026, expanding capabilities for genomic research.

Complete Genomics announces a definitive agreement with Swiss Rockets AG for acquisition, aiming to enhance genomic innovation and market reach.

Complete Genomics collaborates with SOPHiA GENETICS to enhance precision oncology testing solutions. This partnership promises improved accessibility and quality in genomic profiling.

At AMP 2025, Complete Genomics revealed groundbreaking advancements in genomic sequencing tailored for oncology and infectious diseases, showcasing cutting-edge partnerships.

A groundbreaking collaboration between Complete Genomics and SOPHiA GENETICS aims to improve access to precision oncology testing using advanced AI-driven analytics.

Complete Genomics has announced the addition of Gene by Gene to its service provider program at the ASHG Annual Meeting. This collaboration aims to enhance genomic sequencing capabilities.

Complete Genomics has partnered with Velsera to create a comprehensive genetic testing solution utilizing DNBSEQ sequencing technology, enhancing clinical workflows.

Complete Genomics has awarded its Spatial Xcellerator Grant to four innovative research projects focusing on critical health issues. Discover the winners and their impactful research.

Complete Genomics introduces cutting-edge sequencing solutions, DNBSEQ-T1+ and DNBSEQ-E25 Flash, at AGBT 2025, boosting genomic research efficiency.

In 2024, Complete Genomics made significant advancements in its U.S. operations, establishing efficient manufacturing to enhance its NGS solutions.